AROC-3 by Arrowhead Pharmaceuticals for IgA Nephropathy (Berger’s Disease): Likelihood of Approval

AROC-3 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for IgA Nephropathy (Berger’s Disease).

Gabapentinoids may increase hip fracture risk in older adults

The study, published today in JAMA Network Open, tracked patients hospitalized for hip fractures in Victoria, Australia from March 2013 through June 2018, who had

November 14, 2024

Valneva wins FDA approval for the first chikungunya vaccine – Pharmaceutical Technology

Valneva has also applied for marketing approval for Ixchiq in Canada and Europe. Image Credit: frank600 / Getty Images. The US Food and Drug Administration

November 10, 2023

Videra Health Launches AI Digital Health Companion

What You Should Know: – Videra Health has introduced Ava, an AI-powered digital health companion designed to improve patient engagement and care delivery for healthcare

November 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.